Story perspectives

Teva Recalls 580,000 Prazosin Capsules Over Health Risk

11/5/2025

37 3

Summary

Story summary

Teva Pharmaceuticals recalls 580,000 bottles of Prazosin Hydrochloride capsules due to N-nitroso Prazosin impurity C.
The U.S. Food and Drug Administration classifies this recall as Class II, indicating potential temporary health risks.
The affected capsules come in 1 mg, 2 mg, and 5 mg doses nationwide.
Patients should contact pharmacists or healthcare providers to confirm if their medication is affected and should not stop taking it without consulting a professional.

1 of 1

Story summary

Teva Pharmaceuticals recalls 580,000 bottles of Prazosin Hydrochloride capsules due to N-nitroso Prazosin impurity C.
The U.S. Food and Drug Administration classifies this recall as Class II, indicating potential temporary health risks.
The affected capsules come in 1 mg, 2 mg, and 5 mg doses nationwide.
Patients should contact pharmacists or healthcare providers to confirm if their medication is affected and should not stop taking it without consulting a professional.